10-K/A: Aura Biosciences Amends Annual Report to Update Executive Compensation and Ownership Details

Aura Biosciences has filed an amendment to its annual report to update executive compensation details and beneficial ownership information.

Summary

• Aura Biosciences has amended its annual report on Form 10-K for the year ended December 31, 2023.
• The amendment primarily updates executive compensation disclosures to include J. Jill Hopkins, M.D., as a named executive officer and remove Cadmus C. Rich, M.D.
• It also corrects the calculation of option award values in accordance with FASB standards.
• The amendment includes updated certifications from the principal executive officer and principal financial officer.
• The company's named executive officers for 2023 are Elisabet de los Pinos, Ph.D., Julie B. Feder, and J. Jill Hopkins, M.D.
• Elisabet de los Pinos received a total compensation of $3,536,811 in 2023, including a salary of $585,525, stock awards of $1,240,688, and option awards of $1,400,963.
• Julie B. Feder's total compensation was $1,660,859, including a salary of $437,825, stock awards of $496,275, and option awards of $560,385.
• J. Jill Hopkins received a total compensation of $2,935,681, including a salary of $109,375, a sign-on bonus of $200,000, stock awards of $1,210,950, and option awards of $1,365,820.
• The company's aggregate market value of voting common equity held by non-affiliates was $224.6 million as of June 30, 2023.
• As of March 20, 2024, there were 49,504,405 shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The document is a routine amendment to a financial report, indicating a neutral to slightly positive sentiment due to the company's adherence to regulatory requirements and transparency. The correction of errors is a positive sign of diligence.

Positives

• The company is transparently updating its executive compensation disclosures.
• The company is correcting previous errors in option award calculations.
• The company has a formal compensation policy that considers market benchmarks and individual performance.
• The company has a 401(k) plan for employees, including named executive officers.

Negatives

• The need to amend the original report suggests potential errors in the initial filing.
• The company's compensation structure includes significant equity-based awards, which may dilute shareholder value.

Risks

• The company's reliance on equity-based compensation may lead to dilution of shareholder value.
• The company's compensation structure may incentivize short-term performance over long-term strategic goals.
• The company's executive compensation is subject to market fluctuations and may need to be adjusted in the future.

Future Outlook

This document does not contain any forward-looking statements or guidance.

Management Comments

• The Board and Compensation Committee review compensation annually for our executive officers.
• We target a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus or long-term incentives.
• Our Compensation Committee is responsible for determining the compensation for all executive officers.

Industry Context

This amendment is a routine update to comply with SEC regulations regarding executive compensation and ownership disclosures, which is common for publicly traded companies. The company's use of equity-based compensation is typical in the biotech industry to attract and retain talent.

Comparison to Industry Standards

• The compensation structure, including base salary, bonuses, and equity awards, is consistent with industry practices for biotech companies of similar size and stage.
• The use of third-party compensation advisors like Pay Governance is a common practice to ensure competitive compensation packages.
• The vesting schedules for stock options and restricted stock units are standard in the industry, typically vesting over a period of three to four years.
• The company's non-employee director compensation policy, including cash retainers and equity grants, aligns with industry benchmarks for board compensation.

Management Changes

Related Party Transactions

• Matrix Capital Management Master Fund, LP, a significant shareholder, purchased shares in both the 2022 and 2023 public offerings.

Stakeholder Impact

• Shareholders are provided with updated information on executive compensation and ownership.
• Employees are informed about the company's compensation policies and practices.
• The company's transparency in reporting enhances investor confidence.

Next Steps

• The company will continue to monitor and adjust executive compensation as needed.
• The company will continue to comply with SEC regulations and reporting requirements.

Key Dates

Keywords

executive compensation, stock options, restricted stock units, named executive officers, corporate governance, beneficial ownership, financial reporting, SEC filings, Aura Biosciences